<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01194271</url>
  </required_header>
  <id_info>
    <org_study_id>2009-0135</org_study_id>
    <secondary_id>NCI-2010-01974</secondary_id>
    <nct_id>NCT01194271</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Ipilimumab in Prostate Cancer</brief_title>
  <official_title>A Neoadjuvant Phase IIa Study of Ipilimumab {Formerly Known as MDX-010 (BMS-734016)} Plus Hormone Ablation in Men With Prostate Cancer Followed by Radical Prostatectomy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to learn how ipilimumab in combination with&#xD;
      Lupron (leuprolide acetate) affects the body's own defense (immune) system before having&#xD;
      surgery to remove prostate cancer. The safety of the drug combination will also be studied.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Study Drugs:&#xD;
&#xD;
      Ipilimumab is designed to cause an immune response in your body by blocking 2 specific&#xD;
      molecules that usually block an immune response. This may help to kill cancer cells.&#xD;
&#xD;
      Leuprolide acetate is designed to lower the level of testosterone (a male hormone) in the&#xD;
      blood. This may slow the growth of cancer cells.&#xD;
&#xD;
      Study Drug Administration:&#xD;
&#xD;
      If you are found to be eligible to take part in this study, you will receive a leuprolide&#xD;
      acetate injection in your muscle. This is considered Week 0. One week later, you will begin&#xD;
      treatment with ipilimumab. Ipilimumab will be given by vein over 90 minutes during Weeks 1&#xD;
      and 4 (about 21 days apart). During the infusion, your blood pressure will be measured every&#xD;
      30 minutes, and again an hour after you are finished receiving the drug.&#xD;
&#xD;
      Study Visits:&#xD;
&#xD;
      At Weeks 0, 1, 4 and 7, the following tests and procedures will be performed:&#xD;
&#xD;
        -  You will have a physical exam, including measurement of your vital signs and weight.&#xD;
&#xD;
        -  You will be asked about any drugs or treatments you may be receiving.&#xD;
&#xD;
        -  You will be asked about any side effects you may have experienced.&#xD;
&#xD;
        -  Your performance status will be recorded.&#xD;
&#xD;
        -  Blood (about 7-10 tablespoons) will be drawn for routine tests. This blood will also be&#xD;
           tested to measure your protein, PSA and testosterone levels, to check the function of&#xD;
           your thyroid and adrenal glands, and to test for an immune response.&#xD;
&#xD;
      Surgery:&#xD;
&#xD;
      About 4 weeks after your second treatment with ipilimumab, you will have surgery to remove&#xD;
      your prostate gland. You will be asked to sign a separate consent form that describes the&#xD;
      surgery and its risks. A sample of the leftover prostate gland tissue from surgery will be&#xD;
      tested for an immune response. On that day, the following tests and procedures will be&#xD;
      performed:&#xD;
&#xD;
      Between 14 and 24 weeks after your surgery, you will return to the clinic for your&#xD;
      post-operative follow-up visit. The following tests and procedures will be performed:&#xD;
&#xD;
        -  You will have a physical exam, including measurement of your vital signs and weight.&#xD;
&#xD;
        -  Your performance status will be recorded.&#xD;
&#xD;
        -  You will be asked about any drugs or treatments you may be receiving.&#xD;
&#xD;
        -  You will be asked about any side effects you have experienced since your last visit.&#xD;
&#xD;
        -  Blood (about 7-10 tablespoons) will be drawn for routine tests. This blood will also be&#xD;
           used to measure your protein, testosterone and PSA levels, to check the function of your&#xD;
           thyroid and adrenal glands, and to test for an immune response.&#xD;
&#xD;
        -  You will have a bone scan, and either a CT or MRI scan of your chest, abdomen, and&#xD;
           pelvis to check the status of the disease.&#xD;
&#xD;
      Length of Study:&#xD;
&#xD;
      You will only receive 2 treatments with ipilimumab on this study. You will be on study until&#xD;
      24 weeks after surgery. You will be taken off study if intolerable side effects occur, if the&#xD;
      disease gets worse, or if the study doctor thinks it is in your best interest to be taken off&#xD;
      study.&#xD;
&#xD;
      This is an investigational study. Ipilimumab is not FDA approved or commercially available.&#xD;
      Ipilimumab is currently being used for research purposes only. Leuprolide acetate is FDA&#xD;
      approved for management of metastatic prostate cancer but is not approved for use before&#xD;
      definitive surgery. It is commercially available to treat prostate cancer.&#xD;
&#xD;
      Up to 20 patients will take part in this study. All will be enrolled at MD Anderson.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immunologic Response: Number of Participants With Immune Response</measure>
    <time_frame>Baseline to Week 8</time_frame>
    <description>Immunological response assays were measured at several time points starting at baseline until the eighth week after starting the medicine for each participant. The immunological responses measured were Cluster of Differentiation 4 (CD4), Cluster of Differentiation 8 (CD8) and Inducible T-cell Costimulatory (ICOS) markers. T-cells with the CD4 marker help coordinate the immune system response to an invader. Killer T-cells have the CD8 marker and are responsible for killing the invader. ICOS is a molecule which stimulates the activity of the immune response of the killer T-Cells and memory T cells. Participants with at least a 2 fold increase in the presence of CD4, CD8, or ICOS markers from the participant's baseline measure were considered a responder for that marker.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Neoadjuvant Ipilimumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Leuprolide Acetate 22.5 mg administered as a single intramuscular 3 month depot + Ipilimumab 10 mg/kg by vein administered as 2 single doses, 3 weeks apart after hormone therapy + Radical Prostatectomy Surgery to remove prostate gland approximately 4 weeks after the second dose of Ipilimumab.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leuprolide Acetate</intervention_name>
    <description>22.5 mg administered as a single intramuscular 3 month depot.</description>
    <arm_group_label>Neoadjuvant Ipilimumab</arm_group_label>
    <other_name>Lupron Depot</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipilimumab</intervention_name>
    <description>10 mg/kg by vein administered as 2 single doses, 3 weeks apart after hormone therapy.</description>
    <arm_group_label>Neoadjuvant Ipilimumab</arm_group_label>
    <other_name>BMS-734016</other_name>
    <other_name>MDX010</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Radical Prostatectomy</intervention_name>
    <description>Surgery to remove prostate gland approximately 4 weeks after the second dose of Ipilimumab.</description>
    <arm_group_label>Neoadjuvant Ipilimumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Willing and able to give written informed consent;&#xD;
&#xD;
          2. Histologic Documentation: Histologic documentation of prostatic adenocarcinoma.&#xD;
             Patients with small cell, neuroendocrine, or transitional cell carcinomas are not&#xD;
             eligible. All eligible patients must have a known Gleason sum based on biopsy or TURP&#xD;
             at the time of registration.&#xD;
&#xD;
          3. Locally Resectable Disease: Patients must have disease (localized or locally advanced)&#xD;
             which is deemed by the surgeon to be resectable. Lymph node metastasis or lymph nodes&#xD;
             suspicious of harboring metastasis should be deemed surgically resectable by the&#xD;
             surgeon.&#xD;
&#xD;
          4. Determination of high-risk status: Patients must have either: 1) a Prostate biopsy&#xD;
             Gleason sum &gt;/= 8 OR 2) PSA &gt;/= 20.&#xD;
&#xD;
          5. Prior Treatment: No prior treatment for prostate cancer including prior surgery&#xD;
             (excluding TURP), pelvic lymph node dissection, radiation therapy, or chemotherapy.&#xD;
             Patients who have initiated leuprolide acetate within 1 week of signing consent will&#xD;
             be eligible.&#xD;
&#xD;
          6. Patients must be appropriate candidates for radical prostatectomy. Evidence of&#xD;
             underlying cardiac disease should be evaluated prior to enrollment to ensure that&#xD;
             patients are not at high risk of cardiac complications.&#xD;
&#xD;
          7. ECOG performance status of 0 or 1;&#xD;
&#xD;
          8. Required values for initial laboratory tests: a) WBC &gt;/= 3000/uL; b) ANC &gt;/= 1500/uL,&#xD;
             c) Platelets &gt;/= 100 x 10^3/uL; d) Hemoglobin &gt;/= 9 g/dL; e) Creatinine &lt;/= 2.0 x ULN;&#xD;
             f) AST &lt;/= 2.5 x ULN; g) Bilirubin 0 - 1.0 mg/dL, except patients with Gilbert's&#xD;
             Syndrome, who must have a total bilirubin less than 3.0 mg/mL;&#xD;
&#xD;
          9. Men &gt;/= 18 years of age&#xD;
&#xD;
         10. Patients must agree to practice barrier birth control methods while on therapy, prior&#xD;
             to surgery.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any other malignancy from which the patient has been disease-free for less than 5&#xD;
             years, with the exception of adequately treated and cured basal or squamous cell skin&#xD;
             cancer.&#xD;
&#xD;
          2. Autoimmune disease: Patients with a history of Inflammatory Bowel Disease (including&#xD;
             Crohn's disease and ulcerative colitis) are excluded from this study as are patients&#xD;
             with a history of autoimmune disease (e.g., rheumatoid arthritis, systemic progressive&#xD;
             sclerosis [scleroderma], Systemic Lupus Erythematosus, autoimmune vasculitis [e.g.,&#xD;
             Wegener's Granulomatosis]).&#xD;
&#xD;
          3. Known HIV or chronic hepatitis.&#xD;
&#xD;
          4. Any underlying medical condition, which in the opinion of the Investigator, will make&#xD;
             the administration of study drug hazardous or obscure the interpretation of adverse&#xD;
             events, such as a condition associated with frequent diarrhea.&#xD;
&#xD;
          5. Patients who have had a history of acute diverticulitis, intra-abdominal abscess, GI&#xD;
             obstruction, abdominal carcinomatosis which are known risks factors for bowel&#xD;
             perforation, should be excluded from the study.&#xD;
&#xD;
          6. Any non-oncology vaccine therapy used for prevention of infectious diseases (for up to&#xD;
             one month prior to or after any dose of ipilimumab.&#xD;
&#xD;
          7. Concomitant therapy with any of the following: IL-2, interferon or other non-study&#xD;
             immunotherapy regimens; cytotoxic chemotherapy; immunosuppressive agents; other&#xD;
             investigation therapies; or chronic use of systemic corticosteroids (used in the&#xD;
             management of cancer or non-cancer-related illnesses);&#xD;
&#xD;
          8. Previous treatment with other investigational products within 30 days;&#xD;
&#xD;
          9. Previous enrollment in another MDX-010 (BMS-734016) clinical trial or prior treatment&#xD;
             with a CD137 agonist or CTLA-4 inhibitor or agonist&#xD;
&#xD;
         10. Concurrent use of 5-alpha-reductase inhibitors (finasteride, dutasteride).&#xD;
&#xD;
         11. Prisoners or patients who are compulsorily detained (involuntarily incarcerated) for&#xD;
             treatment of either a psychiatric or physical (e.g., infectious disease) illness must&#xD;
             not be enrolled in this study.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Padmanee Sharma, MD, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 1, 2010</study_first_submitted>
  <study_first_submitted_qc>September 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 2, 2010</study_first_posted>
  <results_first_submitted>October 13, 2016</results_first_submitted>
  <results_first_submitted_qc>September 1, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 3, 2020</results_first_posted>
  <last_update_submitted>September 1, 2020</last_update_submitted>
  <last_update_submitted_qc>September 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hormone Ablation</keyword>
  <keyword>Prostate adenocarcinoma</keyword>
  <keyword>Radical prostatectomy</keyword>
  <keyword>Leuprolide Acetate</keyword>
  <keyword>Lupron Depot</keyword>
  <keyword>Ipilimumab</keyword>
  <keyword>BMS-734016</keyword>
  <keyword>MDX010</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ipilimumab</mesh_term>
    <mesh_term>Leuprolide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment period: September 1, 2010 to June 5, 2013. All recruitment done at The University of Texas MD Anderson Cancer Center.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Neoadjuvant Ipilimumab</title>
          <description>Leuprolide Acetate 22.5 mg administered as a single intramuscular 3 month depot + Ipilimumab 10 mg/kg by vein administered as 2 single doses, 3 weeks apart after hormone therapy + Radical Prostatectomy Surgery to remove prostate gland approximately 4 weeks after the second dose of Ipilimumab.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ineligible, Screen Failure</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Two participants are not included in the demographics, excluded from the study due to screening failure or withdraw prior to being assigned any treatment.</population>
      <group_list>
        <group group_id="B1">
          <title>Neoadjuvant Ipilimumab</title>
          <description>Leuprolide Acetate 22.5 mg administered as a single intramuscular 3 month depot + Ipilimumab 10 mg/kg by vein administered as 2 single doses, 3 weeks apart after hormone therapy + Radical Prostatectomy Surgery to remove prostate gland approximately 4 weeks after the second dose of Ipilimumab.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.9" lower_limit="36" upper_limit="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>PSA (Average) Tumor Clinical Stage</title>
          <description>Prostate-specific antigen (PSA) 4 categories for describing the local extent of a prostate tumor, ranging from T1 to T4</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>T1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gleason Score</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lupron Ipilimumab Dose</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>One dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Two doses</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Surgery</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Immunologic Response: Number of Participants With Immune Response</title>
        <description>Immunological response assays were measured at several time points starting at baseline until the eighth week after starting the medicine for each participant. The immunological responses measured were Cluster of Differentiation 4 (CD4), Cluster of Differentiation 8 (CD8) and Inducible T-cell Costimulatory (ICOS) markers. T-cells with the CD4 marker help coordinate the immune system response to an invader. Killer T-cells have the CD8 marker and are responsible for killing the invader. ICOS is a molecule which stimulates the activity of the immune response of the killer T-Cells and memory T cells. Participants with at least a 2 fold increase in the presence of CD4, CD8, or ICOS markers from the participant's baseline measure were considered a responder for that marker.</description>
        <time_frame>Baseline to Week 8</time_frame>
        <population>One participant was not evaluable for outcome due to early death. Of evaluable 16 participants, the number of participants (N) analyzed reflected in CD4, CD8 and ICOS that are associated with immune response.</population>
        <group_list>
          <group group_id="O1">
            <title>Neoadjuvant Ipilimumab</title>
            <description>Leuprolide Acetate 22.5 mg administered as a single intramuscular 3 month depot + Ipilimumab 10 mg/kg by vein administered as 2 single doses, 3 weeks apart after hormone therapy + Radical Prostatectomy Surgery to remove prostate gland approximately 4 weeks after the second dose of Ipilimumab.</description>
          </group>
        </group_list>
        <measure>
          <title>Immunologic Response: Number of Participants With Immune Response</title>
          <description>Immunological response assays were measured at several time points starting at baseline until the eighth week after starting the medicine for each participant. The immunological responses measured were Cluster of Differentiation 4 (CD4), Cluster of Differentiation 8 (CD8) and Inducible T-cell Costimulatory (ICOS) markers. T-cells with the CD4 marker help coordinate the immune system response to an invader. Killer T-cells have the CD8 marker and are responsible for killing the invader. ICOS is a molecule which stimulates the activity of the immune response of the killer T-Cells and memory T cells. Participants with at least a 2 fold increase in the presence of CD4, CD8, or ICOS markers from the participant's baseline measure were considered a responder for that marker.</description>
          <population>One participant was not evaluable for outcome due to early death. Of evaluable 16 participants, the number of participants (N) analyzed reflected in CD4, CD8 and ICOS that are associated with immune response.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CD4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ICOS</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event collection from baseline until 30 days after the last dose of drug, approximately 14 weeks post surgery.</time_frame>
      <desc>Two participants of nineteen registered on the study were excluded prior to any treatment assignment due to screen failure and withdrawal, therefore are not included in adverse event reporting.</desc>
      <group_list>
        <group group_id="E1">
          <title>Neoadjuvant Ipilimumab</title>
          <description>Leuprolide Acetate 22.5 mg administered as a single intramuscular 3 month depot + Ipilimumab 10 mg/kg by vein administered as 2 single doses, 3 weeks apart after hormone therapy + Radical Prostatectomy Surgery to remove prostate gland approximately 4 weeks after the second dose of Ipilimumab.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bilateral pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis/Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Transaminitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Hypophysitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Synocope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory distress syndrome (ARDS)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Padmanee Sharma, Professor, Genitourinary Medical Oncology</name_or_title>
      <organization>The University of Texas (UT) MD Anderson Cancer Center</organization>
      <phone>713-792-2830</phone>
      <email>CR_Study_Registration@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

